Filing identity and reporting period
The supplied filing is Caladrius Biosciences, Inc.’s unaudited Form 10-Q for the quarter ended June 30, 2018, filed August 9, 2018. This conflicts with the request metadata identifying Lisata Therapeutics, Inc. and 2017 Q2; the filing text does not identify Lisata. Confirm the issuer and period before relying on this summary.
Business context and financial performance
Caladrius develops cellular therapies for cardiovascular and autoimmune diseases. Its programs included Phase 2 CD34-cell studies and a Phase 2 Treg study for type 1 diabetes. The former PCT business was sold to Hitachi in May 2017 and is presented as discontinued operations.
| Metric | Three months ended June 30, 2018 | Six months ended June 30, 2018 |
|---|---|---|
| Continuing-operations revenue | No revenue reported | No revenue reported |
| Operating expenses | $4.27 million | $9.43 million |
| Net loss from continuing operations | $4.08 million | $9.06 million |
| Net loss attributable to common stockholders | $4.08 million | $9.06 million |
| Loss per share | $0.42 | $0.95 |
| Cash used in operating activities | Not reported quarterly in the supplied text | $12.18 million |
Revenue-based margins are not meaningful because the continuing business reported no revenue. The 2017 comparative net income—$38.47 million for the quarter and $28.67 million for six months—was substantially affected by the PCT sale, including a $51.7 million gain, and should not be treated as recurring operating performance.
Liquidity, debt, and balance sheet
At June 30, 2018, cash and cash equivalents were $22.73 million and marketable securities were $27.60 million, totaling approximately $50.32 million in cash and securities. Working capital was approximately $45.7 million; total assets were $52.09 million, total liabilities $8.63 million, and stockholders’ equity $43.47 million. Current liabilities were $5.83 million. Current notes payable were $23,289; the filing describes remaining notes as equipment financings. Management stated that existing cash was expected to fund CLBS03 development and other operating expenses for at least the next 12 months following issuance of the financial statements.
Cash, cash equivalents, and restricted cash decreased by $11.44 million during the first half of 2018. The company received $2.5 million from selling its CFC device and received the $5.0 million PCT-sale escrow amount in June 2018. The escrow receipt is a notable one-time cash inflow, not recurring operating cash generation.
Changes, outlook, and risks
- Six-month operating expenses fell 33% year over year, mainly because CLBS03 enrollment and manufacturing costs had been completed; R&D expense declined 45%. Ischemic-repair R&D increased as the company advanced CLBS12 in Japan and initiated CLBS14-CMD.
- For the quarter, operating expenses declined 45% year over year. Management attributed lower G&A partly to a $1.4 million gain on sale of the CFC device; excluding that gain, G&A was slightly higher for the quarter and higher for the half year.
- Management reported CLBS03 enrollment completion at 110 patients and said interim results indicated the therapy remained well tolerated and was non-futile. CLBS12 had Japanese SAKIGAKE designation; CLBS14-RfA received FDA RMAT designation. These designations and interim observations are not approvals or proof of efficacy.
- The company relied on existing cash and anticipated possible additional equity or debt financing, partnerships, asset sales, and grants. It cautioned that financing may not be available on acceptable terms and that equity issuance may dilute shareholders. In August 2018, after quarter-end, it increased its at-the-market offering capacity from $12 million to $25 million.
- Key risks include clinical and regulatory uncertainty, trial execution and enrollment, dependence on funding and strategic arrangements, commercialization prospects, intellectual-property challenges, and privacy/data-protection obligations for clinical information. The filing reported no material change to previously disclosed legal proceedings and no material adverse effect expected from pending claims.
Most important facts to verify
- Resolve the issuer and period mismatch: the supplied document is Caladrius Biosciences’ Q2 2018 10-Q, not a Lisata Therapeutics 2017 Q2 filing.
- Confirm cash runway assumptions against the clinical-development plan, expected spending, and subsequent financing activity.
- Review the full clinical-trial disclosures and subsequent updates for CLBS03, CLBS12, CLBS14-CMD, and CLBS14-RfA.
- Assess the potential dilution and actual usage of the expanded $25 million at-the-market offering.
- Separate recurring operating results and cash burn from PCT-sale effects, escrow proceeds, and the CFC device-sale gain.